

Comments on the Risk of Gout in Patients with Psoriasis [Letter]

Wen-Bin Yeh¹, Wei-Kai Lee^{2,3}, Mei-Chia Chou⁴, I-Ming Jou⁵

¹Emergency department, Kaohsiung Municipal Min-Sheng Hospital, Kaohsiung, Taiwan; ²Emergency Department, Sinying Hospital, Ministry of Health and Welfare, Tainan, Taiwan; ³Min-Hwei Junior College of Health Care Management, Tainan, Taiwan; ⁴Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Pingtung County, Taiwan; ⁵Department of Orthopedics, E-Da Hospital, Kaohsiung, Taiwan

Correspondence: I-Ming Jou, Department of Orthopedics, E-Da Hospital, No. 1, Yida Road, Yanchao Dist, Kaohsiung City, 82445, Taiwan, Email ed109325@edah.org.tw; Mei-Chia Chou, Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Pingtung Branch, No.1. Anping Lane 1. Jousheng Rd., Neipu Shiang, Pingtung County, Taiwan, Email meeichia@gmail.com

Dear editor

We read with great interest the epidemiological study by Wei et al investigating the association between psoriasis and subsequent gout.¹ They indicated that patients with new onset psoriasis had a higher risk of subsequent incidence of gout. We thank the authors for adopting a nationwide database, covering near all Taiwan residents, thus partly avoiding detection bias and providing empirical evidence for this issue. However, we would like to share some ideas.

First, regarding psoriasis, as the researchers stated, a possible inherent limitation of retrospective studies derived electronic medical records is inaccuracy of coding diagnoses and thus misclassification.² The authors controlled for this bias by selecting those with ICD coding of the disease by specialists, such as dermatologists and rheumatologists, with corresponding medication. We commend them for their narrow definition of ICD-disease coding, which is a good model for any future authors planning to conduct claims-based studies. A recent study provided an algorithm that showed a positive predictive value of up to 95% in patients who had more than 1 examination by a dermatologist with psoriasis as the primary diagnostic code and a prescription for vitamin D derivatives as eligible participants.³ Here, we would like to highlight the importance of reporting case ascertainment, where authors can provide positive predictive rates based on ICD coding algorithms or perform sensitivity analyses using different scenarios to make the study results more trustworthy.⁴

Second, there seems to be no accounting for healthcare utilization after index date. Patients with or without psoriasis may have different behavioral and medical utility frequencies and are therefore susceptible to bias in the follow-up examination of their lingering symptoms.

Third, the severity of psoriasis is associated with subsequent metabolic disease,⁵ and it may be of interest to readers if the authors are able to dwell more on the impact of psoriasis severity on gout events.

Although a definitive effect of psoriasis on the risk of gout will require future studies to reach a final conclusion, we thank Wei et al for their excellent work and look forward to their response.

Funding

There is no funding to report.

Disclosure

None of the authors have a competing interest in this communication.

References

1. Wei JC, Chang YJ, Wang YH, Yeh CJ. The risk of gout in patients with psoriasis: a population-based cohort study in Taiwan. *Clin Epidemiol*. 2022;14:265–273. doi:10.2147/CLEP.S346128

2. Icen M, Crowson CS, McEvoy MT, Gabriel SE, Maradit Kremers H. Potential misclassification of patients with psoriasis in electronic databases. *J Am Acad Dermatol.* 2008;59(6):981–985. doi:10.1016/j.jaad.2008.08.034
3. Ham SP, Oh JH, Park HJ, et al. Validity of diagnostic codes for identification of psoriasis patients in Korea. *Ann Dermatol.* 2020;32(2):115–121. doi:10.5021/ad.2020.32.2.115
4. Brown CA, Londhe AA, He F, et al. Development and validation of algorithms to identify COVID-19 patients using a US electronic health records database: a retrospective cohort study. *Clin Epidemiol.* 2022;14:699–709. doi:10.2147/CLEP.S355086
5. Hajiebrahimi M, Song C, Hägg D, Andersson TM, Villacorta R, Linder M. The occurrence of metabolic risk factors stratified by psoriasis severity: a Swedish population-based matched cohort study. *Clin Epidemiol.* 2020;12:737–744. doi:10.2147/CLEP.S252410

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Epidemiology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Epidemiology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical Epidemiology

Dovepress

Publish your work in this journal

Clinical Epidemiology is an international, peer-reviewed, open access, online journal focusing on disease and drug epidemiology, identification of risk factors and screening procedures to develop optimal preventative initiatives and programs. Specific topics include: diagnosis, prognosis, treatment, screening, prevention, risk factor modification, systematic reviews, risk & safety of medical interventions, epidemiology & biostatistical methods, and evaluation of guidelines, translational medicine, health policies & economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Submit your manuscript here: <https://www.dovepress.com/clinical-epidemiology-journal>

<https://doi.org/10.2147/CLEP.S379488>